Literature DB >> 24882516

Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.

Fa-Xing Yu1, Jing Luo2, Jung-Soon Mo1, Guangbo Liu1, Young Chul Kim1, Zhipeng Meng1, Ling Zhao3, Gholam Peyman4, Hong Ouyang5, Wei Jiang6, Jiagang Zhao5, Xu Chen7, Liangfang Zhang8, Cun-Yu Wang9, Boris C Bastian7, Kang Zhang10, Kun-Liang Guan11.   

Abstract

Uveal melanoma (UM) is the most common cancer in adult eyes. Approximately 80% of UMs harbor somatic activating mutations in GNAQ or GNA11 (encoding Gq or G11, respectively). Herein, we show in both cell culture and human tumors that cancer-associated Gq/11 mutants activate YAP, a major effector of the Hippo tumor suppressor pathway that is also regulated by G protein-coupled receptor signaling. YAP mediates the oncogenic activity of mutant Gq/11 in UM development, and the YAP inhibitor verteporfin blocks tumor growth of UM cells containing Gq/11 mutations. This study reveals an essential role of the Hippo-YAP pathway in Gq/11-induced tumorigenesis and suggests YAP as a potential drug target for UM patients carrying mutations in GNAQ or GNA11.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24882516      PMCID: PMC4075337          DOI: 10.1016/j.ccr.2014.04.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  35 in total

1.  Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs).

Authors:  Jung-Soon Mo; Fa-Xing Yu; Rui Gong; Joan Heller Brown; Kun-Liang Guan
Journal:  Genes Dev       Date:  2012-09-12       Impact factor: 11.361

2.  Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.

Authors:  Todd D Prickett; Xiaomu Wei; Isabel Cardenas-Navia; Jamie K Teer; Jimmy C Lin; Vijay Walia; Jared Gartner; Jiji Jiang; Praveen F Cherukuri; Alfredo Molinolo; Michael A Davies; Jeffrey E Gershenwald; Katherine Stemke-Hale; Steven A Rosenberg; Elliott H Margulies; Yardena Samuels
Journal:  Nat Genet       Date:  2011-09-25       Impact factor: 38.330

3.  Genetic and molecular characterization of uveal melanoma cell lines.

Authors:  K G Griewank; X Yu; J Khalili; M M Sozen; K Stempke-Hale; C Bernatchez; S Wardell; B C Bastian; S E Woodman
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-02       Impact factor: 4.693

4.  The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition.

Authors:  Wei Huang; Xianbo Lv; Chenying Liu; Zhengyu Zha; Heng Zhang; Ying Jiang; Yue Xiong; Qun-Ying Lei; Kun-Liang Guan
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

5.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

Authors:  Yi Liu-Chittenden; Bo Huang; Joong Sup Shim; Qian Chen; Se-Jin Lee; Robert A Anders; Jun O Liu; Duojia Pan
Journal:  Genes Dev       Date:  2012-06-07       Impact factor: 11.361

6.  Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP.

Authors:  Eric Miller; Jiayi Yang; Michael DeRan; Chunlei Wu; Andrew I Su; Ghislain M C Bonamy; Jun Liu; Eric C Peters; Xu Wu
Journal:  Chem Biol       Date:  2012-08-09

7.  Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.

Authors:  Fa-Xing Yu; Bin Zhao; Nattapon Panupinthu; Jenna L Jewell; Ian Lian; Lloyd H Wang; Jiagang Zhao; Haixin Yuan; Karen Tumaneng; Hairi Li; Xiang-Dong Fu; Gordon B Mills; Kun-Liang Guan
Journal:  Cell       Date:  2012-08-02       Impact factor: 41.582

8.  Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation.

Authors:  Fa-Xing Yu; Yifan Zhang; Hyun Woo Park; Jenna L Jewell; Qian Chen; Yaoting Deng; Duojia Pan; Susan S Taylor; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2013-06-01       Impact factor: 11.361

9.  cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes.

Authors:  Minchul Kim; Miju Kim; Seunghee Lee; Shinji Kuninaka; Hideyuki Saya; Ho Lee; Sookyung Lee; Dae-Sik Lim
Journal:  EMBO J       Date:  2013-05-03       Impact factor: 11.598

Review 10.  The hippo signaling pathway in development and cancer.

Authors:  Duojia Pan
Journal:  Dev Cell       Date:  2010-10-19       Impact factor: 12.270

View more
  196 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

2.  Alternative Wnt Signaling Activates YAP/TAZ.

Authors:  Hyun Woo Park; Young Chul Kim; Bo Yu; Toshiro Moroishi; Jung-Soon Mo; Steven W Plouffe; Zhipeng Meng; Kimberly C Lin; Fa-Xing Yu; Caroline M Alexander; Cun-Yu Wang; Kun-Liang Guan
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

3.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors:  Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

4.  HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Authors:  Fernanda Faião-Flores; Michael F Emmons; Michael A Durante; Fumi Kinose; Biswarup Saha; Bin Fang; John M Koomen; Srikumar P Chellappan; Silvya Stuchi Maria-Engler; Uwe Rix; Jonathan D Licht; J William Harbour; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

Review 5.  Drug development against the hippo pathway in mesothelioma.

Authors:  Gavitt A Woodard; Yi-Lin Yang; Liang You; David M Jablons
Journal:  Transl Lung Cancer Res       Date:  2017-06

6.  Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer.

Authors:  Sagar R Shah; Jayoung Kim; Paula Schiapparelli; Carla A Vazquez-Ramos; Juan C Martinez-Gutierrez; Alejandro Ruiz-Valls; Kyle Inman; James G Shamul; Jordan J Green; Alfredo Quinones-Hinojosa
Journal:  Mol Pharm       Date:  2019-03-11       Impact factor: 4.939

7.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

8.  Atypical activation of the G protein Gαq by the oncogenic mutation Q209P.

Authors:  Marcin Maziarz; Anthony Leyme; Arthur Marivin; Alex Luebbers; Prachi P Patel; Zhe Chen; Stephen R Sprang; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2018-10-23       Impact factor: 5.157

9.  GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?

Authors:  Matthew G Field; J William Harbour
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

10.  The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.

Authors:  Carsten Gram Hansen; Yuen Lam Dora Ng; Wai-Ling Macrina Lam; Steven W Plouffe; Kun-Liang Guan
Journal:  Cell Res       Date:  2015-11-27       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.